Sign inJoin waitlistJoin the waitlist

Prantesh Jain

Assistant Professor · University at Buffalo School of Medicine

Credentials: · · · · · · ·

History

University at Buffalo School of Medicine
Present
ROSWELL PARK CANCER INSTITUTE
Present

Case Western Reserve University
2018–2021
Hematology and Medical Oncology
Case Western Reserve University/University Hospitals Cleveland Medical Center
2018–2021
Internal Medicine
John H. Stroger Jr. Hospital of Cook County
2010–2013
KASTURBA MED COLL, MANIPAL, KARNATAKA
2005–2009

Research

NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Journal of the National Comprehensive Cancer Network · 2024 · 118 citations
Role of immune-checkpoint inhibitors in lung cancer
Review · Therapeutic Advances in Respiratory Disease · 2018 · First of 3 authors · 102 citations
Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade
Journal for ImmunoTherapy of Cancer · 2020 · 88 citations

Avirup Guha
6 papers
Vamsi Velcheti
6 papers
Afshin Dowlati
4 papers
KB
Kaustav Bera
4 papers · 3 as a resident
Amit Gupta
3 papers
Daniel Addison
3 papers
Grace Dy
3 papers
Guilherme Oliveira
3 papers
NP
Nathan Pennell
3 papers
Sadeer Al-Kindi
3 papers · 3 as a fellow
Edwin Yau
2 papers
Kristin Higgins
2 papers

Clinical trials

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer
Principal investigator · Withdrawn · Phase 2
Roswell Park Cancer Institute
2026–2028
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
Principal investigator · Active not recruiting · Phase 1, Phase 2
Roswell Park Cancer Institute
2016–2027
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
InduPro, Inc.
2026–2028
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2025–2029